Psychedelic Medicine. Research and Review

Psychedelic Review Articles

Clinical research, policy developments, and evidence reviews across ibogaine, psilocybin, 5-MeO-DMT, ayahuasca, and the regulatory landscape of psychedelic medicine.

Medically reviewed by Dr. Arellano, M.D.

Clinical Director, MindScape Retreat · Board-certified physician specializing in ibogaine-assisted detoxification with over 900 patients treated.

Last reviewed: March 2026

Why Progressive Ibogaine Dosing with TA and HCl Changes Everything

A clinical review of how sequential dosing, combining ibogaine hydrochloride for precision calibration with total alkaloid extract for broad neuromodulation, produces safer, more durable outcomes than traditional flood protocols.

Read Article →

Latest Reviews

Ibogaine

January 2026 — 10 min read

GDNF, Dopaminergic Neuroprotection, and the Science Behind Ibogaine's Lasting Effects

How University of Kentucky research on glial cell line-derived neurotrophic factor upregulation explains ibogaine's uniquely durable anti-craving and antidepressant effects, and what this means for Parkinson's and TBI applications.

Read Full Article →

Psilocybin

January 2026 — 9 min read

Psilocybin for Treatment-Resistant Depression. Where the Evidence Stands in 2026

A review of Johns Hopkins, NYU, and Imperial College London data. FDA Breakthrough Therapy designation, MAPS trial outcomes, and what the current evidence supports and does not support regarding psilocybin for MDD.

Read Full Article →

5-MeO-DMT

December 2025 — 11 min read

5-MeO-DMT and the Neuroscience of Ego Dissolution. Clinical Applications

The acute pharmacology of 5-MeO-DMT, its 5-HT2A receptor activity, and how controlled ego dissolution at the clinical level differs from recreational administration. Survey data from Johns Hopkins on sustained wellbeing outcomes.

Read Full Article →

Oregon, Colorado, and Texas. The State of Psychedelic Legalization in 2026

Policy & Regulation

February 2026 — 8 min read

Oregon, Colorado, and Texas. The State of Psychedelic Legalization in 2026

Oregon Measure 109 licensed service centers are operating. Colorado Proposition 122 implementation is underway. Texas Senate Bill 406 passed funding for MDMA and psilocybin veteran research. A state-by-state policy review.

Read Full Article →

Ibogaine

November 2025 — 13 min read

Ibogaine for Parkinson's Disease. Case Evidence and Mechanistic Rationale

Clinical observations from our 10-Day Extended Protocol for Parkinson's patients, motor improvement, tremor reduction, and subjective quality-of-life outcomes, alongside the dopaminergic neuroprotection research that provides mechanistic grounding.

Read Full Article →

Psilocybin

October 2025 — 9 min read

Psilocybin for Alcohol Use Disorder. The NYU Trial and What Follows

NYU's randomized controlled trial demonstrating psilocybin-assisted therapy significantly reduced heavy drinking days versus active placebo. An analysis of effect size, durability, and how this research applies to clinical practice.

Read Full Article →

FDA Path to Ibogaine Approval. What the MAPS MDMA Rejection Means for Ibogaine's Timeline

Policy & Regulation

September 2025 — 10 min read

FDA Path to Ibogaine Approval. What the MAPS MDMA Rejection Means for Ibogaine's Timeline

The FDA's 2024 rejection of MDMA-assisted therapy has recalibrated timelines for psychedelic drug approvals. What this means for ibogaine's regulatory pathway, the ATAI Life Sciences and DemeRx programs, and the role of offshore clinical centers.

Read Full Article →

Regulatory Update, 2026

Psychedelic Policy. State by State

Oregon

Active

Measure 109 service centers licensed and operating. Psilocybin services legal under state framework since January 2023.

Colorado

Active

Proposition 122 (2022) legalizing psilocybin and several other psychedelics. Regulated access program underway.

Texas

In Progress

SB 406 passed 2021 funding psilocybin and MDMA research for veterans. Active legislative expansion discussions.

Federal (FDA)

Monitoring

Psilocybin holds Breakthrough Therapy designation for MDD and TRD. MDMA rejection (2024) has recalibrated timelines.

Research Updates

Subscribe for Updates

New research reviews, policy developments, and clinical insights delivered to your inbox. No marketing. No selling. Only signal on psychedelic medicine.

No spam. Unsubscribe any time.